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PWM7
ECONOMIC BURDEN OF OSTEOPOROSIS,
BREAST CANCER,AND CARDIOVASCULAR
DISEASE AMONG WOMEN
Sasser A1, Birnbaum HG1, Oster EF1, Rousculp M2
1Analysis Group/Economics, Boston, MA, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVES: To investigate the ﬁnancial burden of
osteoporosis, breast cancer, and cardiovascular disease
among women age 50 to 64 years in terms of the direct
health care and indirect work-loss costs to an employer.
METHODS: Administrative medical and disability claims
data from seven large employers (n > 600,000) were ana-
lyzed between 1998 and 2000. Patients were identiﬁed as
female beneﬁciaries, age 50 to 64 years, who were
enrolled in a managed indemnity health plan. Treatment
samples were deﬁned using ICD-9 codes to identify prin-
cipal diagnoses for each of the three study conditions and
then compared to a random sample of women, age 50 to
64 years. RESULTS: For the year 2000, osteoporosis
patients had direct medical care costs that were $2277
greater than those for the random sample ($4543 versus
$2266, P < 0.05). For breast cancer, the difference was
$12,379 (P < 0.05), with hospital outpatient costs
accounting for the largest share of total costs (43%). For
cardiovascular disease the difference was $12,814 (P <
0.05), with hospital inpatient costs accounting for the
largest share of total costs (48%). The average number
of medical claims per patient was 18.6 for the random
sample, compared to 38.4 for osteoporosis patients, 76.0
for breast cancer patients, and 67.0 for cardiovascular
patients (P < 0.05). Ongoing research will control for
demographic characteristics using multivariate regression
and also explore differences in medically related work
absence costs. CONCLUSIONS: Women beneﬁciaries,
age 50 to 64 years, treated for osteoporosis, breast cancer,
and cardiovascular disease impose a signiﬁcant ﬁnancial
burden on employers. This burden is due to higher levels
of both inpatient and outpatient health care utilization
compared to a random sample of similar patients.
PWM8
THE LIFETIME MEDICAL COSTS OF WOMEN:
CARDIOVASCULAR DISEASE, DIABETES,AND
STRESS URINARY INCONTINENCE
Birnbaum H, Leong S, Kabra A
Analysis Group/Economics, Boston, MA, USA
OBJECTIVE: The purpose of this study was to generate
the ﬁrst estimates of the lifetime medical costs of treating
women with either cardiovascular disease (“CVD”), 
diabetes, or stress urinary incontinence (“SUI”).
METHODS: Women under age 65 years, who have been
treated for CVD, diabetes, or SUI, were identiﬁed using
administrative medical claims data from a large employer
(n > 100,000). A case-control methodology was used 
to estimate the annual medical costs of these women.
Annual estimates were then calculated for women 65
years and older based on a set of assumptions and pub-
lished government statistics. An incidence-based method-
ology with steady-state assumptions was used to project
these annual costs to the lifetime medical costs of treat-
ing women with CVD, diabetes, or SUI. Costs are incre-
mental and are estimated as the additional costs incurred
by patients, as compared to demographically similar con-
trols without the condition. The methodology used does
not account for cost inﬂation, technological change, or
the time value of money. RESULTS: The lifetime costs
associated with CVD, diabetes, and SUI are substantial.
CVD is the most expensive condition on a lifetime basis,
followed by diabetes, and then SUI. The incremental 
lifetime medical cost of treating a woman with CVD (in
2002 dollars) is $423,000. The lifetime cost of treating 
a woman with diabetes is $233,000 and with SUI is
$58,000. CONCLUSIONS: These ﬁndings are the ﬁrst
estimates of the lifetime medical cost burden of three
chronic conditions suffered by women. The levels of these
costs suggest the need for further research and method-
ological reﬁnements to increase awareness of the lifetime
burden of chronic conditions.
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ECONOMIC IMPACT OF SILDENAFIL CITRATE
ON A PHARMACY BUDGET
Cooke C1,Wong W2, Lee H3, Duttagupta S4
1Pﬁzer Inc, Ellicott City, MD, USA; 2CareFirst BlueCross
BlueShield, Baltimore, MD, USA; 3University of Maryland
School of Pharmacy, Ellicott City, MD, USA; 4Pﬁzer Inc, New
York, NY, USA
OBJECTIVES: CareFirst BlueCross BlueShield serves 
3.1 million members in Maryland, Washington, D.C.,
Virginia, and Delaware. The organization provides pre-
scription coverage for 1.1 million members and faces 
spiraling pharmacy expenditures. There has been consid-
erable debate about insurance coverage of sildenaﬁl
citrate, and CareFirst has added this agent to the second
tier of the formulary with restriction. There is a quantity
limit of six tablets per month (or 18 tablets per three
months). However, self-funded accounts have the option
of not including this management tool as part of their pre-
scription beneﬁt. This report analyzes the economic
impact of sildenaﬁl citrate on a pharmacy’s budget.
METHODS: All prescription claims data for sildenaﬁl
citrate were obtained for the year 2001. The claims ﬁle
was imported into an Access database for abstraction of
required data. RESULTS: There were 65,222 prescription
claims for sildenaﬁl citrate in 2001, with each member (N
= 19,646) averaging 3.3 ± 2.7 prescriptions. CareFirst
spent almost $2.6 million on sildenaﬁl citrate, equating
to $2.31 per member per year (PMPY), or $0.19 per
member per month (PMPM). Thus, sildenaﬁl citrate pre-
scriptions constituted approximately 0.5% of the 2001
pharmacy budget. A total of 1.4% of prescriptions (n =
891) were written for 25-mg sildenaﬁl citrate, compared
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with 48.6% (n = 31,717) and 50.0% (n = 32,614) for the
50-mg and 100-mg doses, respectively. Ninety-four
percent of prescriptions were ﬁlled with six tablets, and
only 2% of prescriptions (n = 1309) exceeded the quan-
tity vs. time limit. Members paid an average copay of $13
per prescription. CONCLUSIONS: This estimate of
PMPM cost falls within the range previously reported in
the literature. In comparison with PMPM costs reported
for other drug classes, such as proton pump inhibitors or
cyclooxygenase-2 inhibitors, the amount spent on silde-
naﬁl citrate is considerably lower and of lesser concern to
the pharmacy budget.
PWM10
COST OF ACCESS BY FORMULARY TYPE:
A CASE STUDY OF SILDENAFIL CITRATE 
IN A LARGE MANAGED CARE 
ORGANIZATION
Benson S1, Duttagupta S2, Poller L2
1Pﬁzer Inc, Woodbury, MN, USA; 2Pﬁzer Inc, New York, NY,
USA
OBJECTIVES: Managed care organizations (MCOs)
have traditionally used various types of formulary access
to control cost, with varied success. In this case study, we
determined the actual economic impact of adding silde-
naﬁl citrate to the formulary of a large national MCO by
types of access status. METHODS: Claims data for silde-
naﬁl prescriptions were analyzed for the 12-month period
from August 2001 through July 2002 for this MCO 
and for 7 of its regional areas. Per member per month
(PMPM) costs of sildenaﬁl coverage were calculated by
various formulary status at both the regional and national
levels. RESULTS: The MCO did not require prior autho-
rization for sildenaﬁl prescriptions but did impose restric-
tions on the number of sildenaﬁl tablets per monthly
prescription cycle. The MCO used open, closed, and
incented formularies to control access to sildenaﬁl. Mean
number of sildenaﬁl tablets/month varied from 4.9 to 
6.7 tablets. PMPM costs of sildenaﬁl coverage for the
regional areas were $0.07, $0.11, $0.11, $0.14, $0.15,
$0.15, and $0.18. Type of formulary did not fully explain
variance in costs between regions. In 5 of the 7 areas in
which most patients were covered under an incented for-
mulary, PMPM costs of sildenaﬁl coverage ranged from
$0.11 to $0.15. In the 2 regions with the greatest per-
centage of patients covered under a closed formulary
plan, PMPM costs of sildenaﬁl coverage were $0.07
(44% closed) and $0.15 (54% closed). Whereas in the 3
regions with the most patients covered under an open for-
mulary, PMPM costs of sildenaﬁl coverage were $0.11
(27% open), $0.14 (30% open), and $0.15 (30% open).
CONCLUSIONS: PMPM costs did not vary substan-
tially, regardless of different types of formulary access.
Moreover, in line with ﬁndings from local and employer-
based healthcare plans, addition of sildenaﬁl coverage by
this large MCO resulted in lower than expected PMPM
costs.
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COST IMPLICATION OF UNRESTRICTED
ACCESS TO SILDENAFIL CITRATE IN FOUR
EMPLOYER GROUP PRESCRIPTION PLANS
Cherayil G1, Duttagupta S2
1Pﬁzer Inc, Brookﬁeld, WI, USA; 2Pﬁzer Inc, New York, NY,
USA
OBJECTIVE: The perception persists among employers
and beneﬁt managers that the addition of sildenaﬁl citrate
adds signiﬁcant cost to their prescription plans. A Disease
Therapy Evaluation is a focused analysis of a drug’s per-
formance in a target patient population and provides
healthcare managers with information that may lead to
better decisions for the individual patient as well as the
healthcare organization. The analysis presented here eval-
uates the per member per month (PMPM) cost of silde-
naﬁl without restriction limits on the quantity of tablets
dispensed. METHODS: This retrospective review covered
all sildenaﬁl claims of employees obtained from prescrip-
tion beneﬁt managers. Prescription claims were obtained
for a 6-month interval from December 1999 to May 2000
and imported into an Access database for abstraction of
required data. RESULTS: Data were combined from 4
prescription plans (3 from the Midwest, 1 from the West
Coast) with 361,237 members overall. There were 3477
sildenaﬁl claims in the 6-month period, made by 1493
patients (representing 0.4% of all members). Most of the
prescriptions were for the 50-mg (range for 4 plans,
45%–62%) and 100-mg doses (37%–65%) of sildenaﬁl,
with 1% to 2.5% for the 25-mg dose. On average, 6 to
11 tablets were dispensed at a time, with a range from 1
to 100 tablets. The average cost per prescription varied
from a low end of $50 to a high end of $88; the PMPM
cost ranged from $0.03 to $0.24. CONCLUSIONS: The
actual PMPM cost is markedly lower than the expected
projections, despite the fact that no quantity limits were
imposed. The costs shown here do not take into account
any rebates or other contracting beneﬁts. Thus, employ-
ers may wish to consider the addition of sildenaﬁl to their
beneﬁt package, as it may increase employee satisfaction
without a large impact on the budget.
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LONGITUDINAL DIFFERENCES IN
PSYCHOLOGICAL ADJUSTMENT FOR MEN
WITH ERECTILE DYSFUNCTION: RESULTS
FROM EXCEED
Wallace KL1, Latini DM2, Penson DF3, Lubeck DP2,
Henning JM1, Lue TF2
1TAP Pharmaceutical Products Inc, Lake Forest, IL, USA;
2University of California, San Francisco, San Francisco, CA,
USA; 3VA Puget Sound Health Care System / University of
Washington, Seattle, Seattle, WA, USA
